Search PubMed⌕ Search

Biomedical subjects

G Medley

Publications and source records attributed to G Medley.

At least 55 records · Page 3Linked to original sources
PubMed1986

Prospective evaluation of risk of cervical cancer after cytological evidence of human papilloma virus infection.

846 women with cytological evidence of human papillomavirus infection on their Papanicolaou smears in 1979 were followed for the subsequent development of cervical malignant disorders. Carcinoma-in-situ developed in 30 women during the next 6 years, compared with an expected number of 1.9 by general population incidence figures, giving a relative risk of 15.6. The risk was greatly increased (38.7) in women younger than 25 years when the cytological diagnosis of human papillomavirus infection was made.

Adolescent↗
PubMed1985

Density-dependent fecundity in Schistosoma mansoni infections in man.

An analysis is presented of autopsy data collected by Cheever in 1968 on the association between Schistosoma mansoni worm burdens and faecal egg counts. Significant negative relationships are found between the number of eggs/worm pair/g faeces and both the number of worm pairs and the total number of worms. A general, non-linear, statistical routine is shown to be the most practical method of fitting non-linear models to the observed density-dependent fecundity relationship. The conceptual and practical implications of density-dependence are discussed in the context of epidemiological field studies and chemotherapy programmes.

Animals↗
PubMed1985

Non-Hodgkin's lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease.

A prospective pilot study of 23 patients with non-Hodgkin's lymphoma involving the stomach was undertaken to assess the efficacy of surgical resection followed by chemotherapy with adjuvant cyclical cyclophosphamide, vincristine, and prednisolone (CVP) in early stage disease, and cyclical cyclophosphamide, vincristine, prednisolone, and doxorubicin (CHOP) in advanced disease. One of 18 evaluable patients died postoperatively; 17 of 18 completed therapy and are alive and disease-free at a median follow-up of 41 months after surgery (range, 5 to 111 months), including four patients with stage IV disease who remain in complete remission 19 to 47 months after surgery. There was one postoperative death, giving an actuarial survival rate of 94% in the study group. Three of five inoperable patients were treated with CHOP, with two achieving complete remission. Two untreated patients died. Overall actuarial disease-free survival was 82.6%. Surgical resection plus chemotherapy is capable of producing long-term remission and cure in both localized and advanced non-Hodgkin's lymphoma of the stomach. Intensive supportive care plus chemotherapy may salvage a proportion of patients with inoperable tumors.

Actuarial Analysis↗
PubMed1984

Deoxycytidylate deaminase activity in lymphoproliferative disorders.

The activity of dCMPase has been measured in cell extracts from human lymphoproliferative disorders. The highest levels occurred in T helper-CLL and Thy-ALL, but high levels were also found in C-ALL, NPDLL transforming to DHL, DPDLL and DHL. A range of enzyme activities was found in the majority of types examined, with the widest range encountered in ALL, NPDLL and DHL. In DWDLL, a narrow range of dCMPase activities was found, with enzyme levels in the control range or moderately increased. Similarly, B-CLL exhibited a narrow range of enzyme activities, within that of the controls. The highest enzyme activity in HD was found in the highly malignant type - lymphocyte depleted HD. Statistically significant differences were found between the distribution of dCMPase activities in ALL and the chronic leukemias; and between favorable histologic types of non Hodgkin's lymphomas and the unfavorable DHL type. These data suggest that dCMPase activity is a marker of the clinical aggression of human lymphoid malignancies. Moreover, the marked variation in enzyme activity in each type of lymphoid malignancy suggests that this also applies to individual tumors as well. In view of the important role of dCMPase in pyrimidine metabolism and the profile of enzyme activities in leukemia and lymphoma, it is suggested that an inhibitor of dCMPase could be of clinical value in lymphoid malignancy.

DCMP Deaminase↗
PubMed1982

Clinical relevance of markers of cell proliferation in human lymphoid malignancies: a concise review.

The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness.

Adult↗
PubMed1982

Dysgerminoma--gonadoblastoma and familial 46XY pure gonadal dysgenesis: case report and review of the genetics and pathophysiology of gonadal dysgenesis and H-Y antigen.

46XY gonadal dysgenesis is a rare condition of intersexuality first described in detail by Swyer in 1955. It is characterized by a phenotypic female who is tall, eunuchoid with normal female external genitalia, hypoplastic uterus and Fallopian tubes, streak ovaries and primary amenorrhoea. The patients exhibit none of the associated congenital defects such as webbing of the neck and genu valgum seen in Turner's syndrome. Although rare, this clinical entity is important to recognize because of the high incidence of gonadoblastomas and subsequent development of dysgerminoma. The condition may be familial and therefore siblings need to be screened. To the geneticists and scientists researching in the area of intersexuality, hermaphroditism and sexual determination, it has helped to unveil the mechanisms of gonadal and genital sexual development.

Adolescent↗
PubMed1981

Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

To determine whether kinase (TK) isozyme status adds clinically useful information in adult non-Hodgkin's lymphoma (NHL), we have analyzed peripheral blood plasma and lymphocytes of 44 patients with NHL for either TK1 or TK2 isozyme activity. On the basis of isozyme status, patients could be divided into two groups that did not differ significantly with respect to known determinants for survival. The median survival of patients exhibiting peripheral blood TK1 thymidine kinase activity was 40 wk and that of individuals with TK2 activity was in excess of 200 wk. These data suggest that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.

Humans↗
PubMed1981

Thymidine kinase isoenzymes in human malignant lymphoma.

The activities of thymidine kinase (TK) isoenzyme 1 and 2 were examined in extracts of human benign or malignant lymphoid tissue and correlated with degrees of morphological differentiation. TK2 activity occurred in peripheral blood lymphocytes of normal individuals, patients with chronic lymphocytic leukemia, or solid lymphoid tissue, exhibiting either nonneoplastic histological findings or those of diffuse well-differentiated lymphocytic lymphoma. TK1 activity occurred in solid, non-Hodgkin's lymphoma tissue, exhibiting lesser degrees of cellular differentiation, or in peripheral blood lymphocytes of patients with clinical aggressive chronic lymphocytic leukemia or lymphosarcoma leukemia. In non-Hodgkin's lymphoma tissue, the range of TK1 activities correlated broadly with the Rappaport classification, with higher values occurring in tissue exhibiting changes of diffuse poorly differentiated lymphocytic lymphoma or diffuse histiocytic lymphoma.

Adenosine Triphosphate↗
PubMed1975

A membrane permeability test for the detection of cell surface antigens.

A convenient microtest is described which utilizes antibody-mediated release of [14C]nicotinamide ([14C]NA) from target cells for the detection of cell surface antigens. This test is considerably more sensitive and faster than the widely used 51Cr release test because most of the [14C]NA is rapidly released from the target cells in the initial phase of membrane permeability changes induced by activated complement, as distinct from the colloid osmotic phase of complement-mediated cytolysis.

Animals↗
PubMed1975

Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay.

Both phagocytic and non-phagocytic effector cells were able to kill rabbit antibody-coated chicken erythrocytes (CRBC) while only non-phagocytic effector cells were active against alloantibody-coated SL2 lymphoma. In addition to the variation in susceptibility of erythrocyte and tumour target cells to various effector cell populations, it was found that different tumour cells can vary markedly in their ability to be killed by non-immune spleen cells in the presence of antibody. It is postulated that both the type of antibody and certain characteristics of the cell membrane are important in determining whether target cells are susceptible to antibody-dependent cell-mediated cytotoxicity detected by the 51Cr release assay. It was also demonstrated that alloantibody-coated P-815-Y mastocytoma, which showed very little evidence of cytotoxicity in the 51Cr release assay, was markedly inhibited in its ability to incorporate [125I]IUdR after incubation with antiserum and non-immune spleen cells. This growth inhibition in the absence of cytotoxicity, or cytostasis, is discussed in relation to the potential mechanisms of target cell damage, and in the light of recent observations (Plata, Gomard, LeClerc and Levy, 1974; Newlands and Roitt, 1975) that cytotoxicity and growth inhibition assays detect different effector cell populations in tumour-bearing animals.

Animals↗
PubMed1973

Growth inhibition of murine tumor cells, in vitro, by puromycin, ( 6 N)O 2 '-dibutyryl 3',5'-adenosine monophosphate, or adenosine: evidence of commitment for cell division.

The cytostatic effects of puromycm, [(6)N]O(2')-dibutyryl 3',5'-adenosine monophosphate, and adenosine on asynchronous and synchronous cultures of the murine mastocytoma, P815Y, have been studied. Cell growth was arrested after a minimum of one further division. A model is proposed for the inhibition of cell division in which the periods of inhibition and growth arrest are separated in time by one cell cycle.

Adenosine↗